Trial Profile

A phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study of BCX10013 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BCX-10013 (Primary)
Indications Immunological disorders
Focus Adverse reactions

Most Recent Events

03 Nov 2023 According to a BioCryst Pharmaceuticals media release, the company plans to present data from the recently completed 160 mg cohort of its multiple ascending dose healthy volunteer trial at the R and D day.
03 Aug 2023 According to a BioCryst Pharmaceuticals media release, the company plans to complete an additional cohort of its multiple ascending dose trial (MAD) of BCX10013, at a higher dose (160 mg QD), in healthy volunteers to provide further information to the pharmacokinetic model.
14 Jan 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com